

Tables, Figures, and Map

TABLES

- 1.1 Incomes of the University of Cambridge, 2011–12 10
- 2.1 Factors affecting the university's commercialization ability 17
- 4.1 Yale Biotechnology companies by venture capital funding 70
- 4.2 OCR activities, 1996–2012 78
- 4.3 Yale University, highest-paying licenses in life sciences and biotechnology 78
- 5.1 University of Cambridge's share of revenues from net royalties where Cambridge Enterprise is involved in the exploitation 101
- 5.2 University of Cambridge's share of revenues from net royalties where Cambridge Enterprise is not involved in the exploitation 102
- 5.3 University of Cambridge income, 2011–12 104
- 5.4 Cambridge biotechnology companies by venture capital funding, 1996–2012 106
- A2.1 Interview distribution 148
- A2.2 List of interviewees at Yale 150
- A2.3 List of interviewees at Cambridge 151

FIGURES

- 1.1 University of Cambridge by patents, 1989–2012 10
- 2.1 Internal university technology commercialization factors 24

- 2.2 Technology-transfer culture 27
- 2.3 Cambridge and Yale income changes, 1999–2010 30
- 2.4 Technology-transfer policy 31
- 2.5 Technology-transfer organization 38
- 2.6 Theoretical approach 40
- 3.1 R&D in universities by funding source 46
- 3.2 Growth in the establishment of technology-transfer offices after Bayh-Dole 47
- 3.3 Research funding at UK universities, 1994–2012 52
- 3.4 UK universities' patents, 1990–2004 57
- 3.5 Sources of academic R&D in the United States, 2011 58
- 3.6 UK research grants and contracts income of HEIs, 2011–12 59
- 4.1 Yale by patents, 1977–2012 79
- 4.2 How a Yale royalty deal works 80
- 4.3 Yale University biotechnology spin-outs, 1976–2011 81
- 4.4 The biotechnology cluster in the New Haven metropolitan area by sector 84
- 4.5 New Haven biotechnology companies by location 86
- 5.1 Cambridge University biotechnology spin-outs 107
- 5.2 University of Cambridge technology-transfer organization, 1970–2006 113
- 5.3 Biotechnology companies' view on the importance of the University of Cambridge to the development of the cluster 117
- 5.4 The biotechnology industry's view on technology-transfer changes at Cambridge 117
- AI.1 University of Cambridge organizational chart 145
- AI.2 Yale University organizational chart 146

MAP

- 4.1 The New Haven biotechnology cluster, 2004 82